H.R. 5999: To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to furnish an opioid antagonist to a veteran without requiring a prescription or copayment.

This bill aims to modify the existing regulations under title 38 of the United States Code, specifically focusing on the provision of opioid antagonists, which are medications used to counteract opioid overdoses. The key aspects of the bill can be summarized as follows:

1. Providing Opioid Antagonists

The bill mandates that the Secretary of Veterans Affairs must supply opioid antagonists to veterans. Importantly, this provision will be made without the need for a prescription. This change simplifies accessibility for veterans who may need these life-saving medications.

2. Removal of Copayment Requirement

In addition to providing opioid antagonists without a prescription, the bill also eliminates the requirement for veterans to make a copayment for these medications. This means that veterans would receive opioid antagonists at no cost, further improving access to these critical drugs.

Overall, the bill is designed to enhance the response to opioid overdoses among veterans by ensuring easier access to opioid antagonists, thereby potentially reducing the incidence of fatal overdoses within this population.

Relevant Companies

• AMGN (Amgen Inc.): As a manufacturer of opioid antagonists, Amgen could see changes in demand for its products due to this legislation, potentially influencing its revenue from these medications.
• MRK (Merck & Co., Inc.): Merck may also be impacted as they are a producer of drugs related to opioid antagonists; increased distribution could affect their market dynamics.